GCcell to Host IR Pitching and Networking Event and Participate with Exclusive Booth at BIX 2025

Global clinical trial specimen analysis organization GCCL announced on September 18 that it will participate with an exclusive booth at BioPlus-InterPhex Korea 2025 (BIX 2025), the largest domestic bio convention, to be held at COEX from the 15th to the 17th of next month. On the 16th of the same month, GCCL will also host an exclusive IR pitching and networking event.

Global clinical trial specimen analysis organization GCCL will participate with an exclusive booth at BioPlus-InterPhex Korea 2025 (BIX 2025), the largest domestic bio convention, held at COEX from the 15th to the 17th of next month. GCCL

BIX 2025, hosted by the Korea Biotechnology Industry Organization, will feature a variety of programs including keynote speeches, expert sessions, exhibitions, partnering meetings, and receptions. A total of 300 companies from 15 countries will participate, making it the largest event to date with over 550 booths.

On the second day of the event, at 4 p.m. on the 16th of next month, GCCL will exclusively host the "IR Pitching & Networking Event with GCCL" at Studio159 on the second floor of COEX. Around 100 representatives from domestic and international pharmaceutical and biotech companies, as well as investment firms, are expected to attend, where they can directly explore innovative technologies and business models and seek strategic partnerships for future growth. The event will include IR presentations by pharmaceutical and biotech companies and open networking sessions. GCCL is currently recruiting participants who wish to attend this event.

During the convention, GCCL will operate a large exclusive exhibition booth, showcasing its all-in-one solutions for global clinical trial specimen analysis, including Central Lab, Bioanalysis, and R&D services. Through this, GCCL plans to highlight its strength in providing reliable integrated analysis services covering specimen transportation, analysis, and data management, based on extensive collaboration experience with domestic and international new drug development companies.

Notably, at this exhibition, GCCL will introduce a new interactive lab tour utilizing touchscreens, allowing visitors to intuitively experience GCCL’s analysis processes and services. The company will emphasize its competitiveness based on international quality standards such as full-range GCLP (Good Clinical Laboratory Practice) certification, advanced analytical equipment, and optimized IT systems. GCCL aims to further strengthen its differentiated position and expertise in the domestic and global clinical trial markets.

GCCL CEO Cho Kwanku stated, "BIX 2025 is an important platform to directly engage with the global pharmaceutical and biotech industries and showcase GCCL's expertise and integrated analysis solutions. In particular, through this IR pitching and networking event, we aim to expand strategic partnerships with domestic and international companies and further enhance GCCL's global competitiveness in the field of clinical trial specimen analysis."

Meanwhile, GCCL is a clinical trial specimen analysis organization that has obtained full-range GCLP certification from the Ministry of Food and Drug Safety, providing customized clinical analysis services that meet global standards for all phases of clinical trials, from Phase 1 to Phase 4. Based on a variety of analytical platforms that meet global quality standards, such as the introduction of ddPCR devices, as well as specialized specimen analysis and method development services, GCCL supports clinical trial specimen analysis not only for domestic pharmaceutical and biotech companies but also for partners across Asia and worldwide.